Yes

Faculty will critically evaluate current evidence, including trial data, biomarkers, and patient selection considerations, to clarify where immunotherapy offers meaningful benefit and where uncertainty remains in the treatment of triple-negative breast cancer. Presenters will provide expert insight into translating evolving data into real-world clinical decision-making. Through this balanced discussion, participants will gain a nuanced understanding of the risks, benefits, and limitations of universal versus selective use of immune checkpoint inhibitors in TNBC. Explore the rationale and evidence behind the use of immune checkpoint inhibitor therapy in patients with TNBC. Discussion will review key clinical trial data, mechanisms of action, and the role of biomarkers in guiding treatment decisions. Faculty will also address ongoing controversies, including patient selection, toxicity considerations, and real-world applicability. Participants will gain a clearer understanding of the potential benefits and limitations of broadly applying immunotherapy across the TNBC population.